#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Metastatic Renal Cell Carcinoma Treated with Everolimus – Data from the RENIS Clinical Registry


Authors: T. Büchler 1;  L. Dušek 2;  J. Fínek 3;  A. Poprach 4;  D. Budňáková 2;  V. Kandrnal 2;  J. Jarkovský 2;  Z. Bortlíček 2;  D. Klimeš 2;  J. Abrahámová 1;  R. Vyzula 4
Authors‘ workplace: Onkologické oddělení, Fakultní Thomayerova nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha 1;  Institut biostatistiky a analýz, Lékařská a Přírodovědecká fakulta Masarykovy univerzity, Brno 2;  Radioterapeutické a onkologické oddělení, Fakultní nemocnice Plzeň 3;  Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno 4
Published in: Klin Onkol 2011; 24(5): 389-392
Category: Reports from Clinical Registries

Overview

Everolimus is an oral mTOR kinase inhibitor approved for the treatment of patients with meta­static renal cell carcinoma (mRCC) progressing during or after treatment with vascular endothelial growth factor (VEGF)-targeted agents. Using the national RENIS clinical registry, we have retrospectively analysed outcomes of patients treated for mRCC with everolimus. A total of 78 patients were evaluable. Median progression-free survival from the start of everolimus therapy was 7 months (95% confidence interval 2–12 months). Partial response or stable disease was achieved in 69% of patients. Treatment toxicity was predictable and serious adverse events occurred in only 6% of patients the most common being respiratory toxicity. Everolimus therapy provides significant clinical benefit for heavily pretreated mRCC patients after failure of VEGF-targeted therapy

Key words:
everolimus – renal cell carcinoma – therapy

The team of autors declares a support of Novartis.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Submitted:
14. 6. 2011

Accepted:
18. 7. 2011


Sources

1. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372(9637): 449–456.

2. Afinitor – souhrn infomací o přípravku. Poslední aktualizace 17. 05. 2010. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/001038/WC500022814.pdf.

3. Dušek L, Mužík J, Gelnarová E et al. Cancer incidence and mortality in the Czech Republic. Klin Onkol 2010; 23(5): 311–324.

4. Gabardi S, Baroletti SA. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology. Pharmacotherapy 2010; 30(10): 1044–1056.

5. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010; 116(18): 4256–4265.

6. Beaumont JL, Butt Z, Baladi J et al. Patient-reported outcomes in a phase iii study of everolimus versus placebo in patients with metastatic carcinoma of the kidney that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy. Oncologist 2011; 16(5): 632–640.

7. Buchler T, Klapka R, Melichar B et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma – data from the Czech registry. Ann Oncol. 2011. Epub ahead of print.

8. White DA, Camus P, Endo M et al. Noninfectious pneu­monitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010; 182(3): 396–403.

Labels
Paediatric clinical oncology Surgery Clinical oncology
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#